The 2 most recent market catalysts affecting $RANI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 65
Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6
Chardan Capital's initiation of coverage on Rani Therapeutics Holdings with a 'Buy' rating and a $6 price target is a positive development for the company. Analyst coverage, especi…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 85
Rani Therapeutics Hldgs Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.708M Beat $925.000K Estimate
Rani Therapeutics Holdings (RANI) announced Q2 earnings that surpassed analyst expectations on both the top and bottom lines. The company reported a loss of $(0.04) per share, beat…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.